An open clinical trial
The patients with PCOS will be recruited to receive folic acid (45 patients) and equal number will receive no folic acid
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
Tablet 5 mg
Saad Abul ella fertility Centre
Khartoum, Sudan
RECRUITINGpregnancy rates
Pregnancy rates will be compared in the treatment group and control group
Time frame: 3 months
Ovulatory pattern improvements
Ovulatory pattern will be assessed based on the history of the PCOS patients, the patients whom were having baseline oligomenorrhea or amenorrhea will be re-assessed for resuming regular cycles defined as periods lasting 22 - 35 days. this pattern improvement will be compared in the treatment group and control group using questionnaire
Time frame: 3 months
Clinical signs of hyperandrogenemia
Hirsutism will be used as a sign of hyperandrogenemia, Patients will be provided with modified Ferriman -Gallwey (mFG) images to self-rate hair growth in each of the 9 body areas (upper lip, chin, chest, upper and lower back, upper and lower abdomen, thighs, and upper arms). For each site, a score on a scale of 0 to 4 was recorded. A total score of 8 or greater is defined as clinical evidence of hirsutism; scores from 8 to 15 are considered mild hirsutism; scores from16 to 25 are considered moderate; and scores from 26 to 36 are considered severe hirsutism. The baseline and after 3 months hirsutism compared in the treatment group and control group
Time frame: 3 months
Plasma level of testosterone
Plasma level of testosterone will be compared in the treatment group and control group
Time frame: 3 months
Plasma level of insulin
Plasma level of insulin will be compared in the treatment group and control group
Time frame: 3 months
Plasma level of follicle-stimulating hormone (FSH)
Plasma level of follicle-stimulating hormone will be compared in the treatment group and control group
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 3 months
Plasma level of luteinizing hormone (LH)
Plasma level of luteinizing hormone will be compared in the treatment group and control group
Time frame: 3 months